Vivid Dx is a diagnostics company that focuses on pathogen detection and antimicrobial resistance testing services.
Vivid Dx has raised $15.0M in total funding. The most recent round was Seed. The last funding was announced in July 2026.
Vivid Dx's investors include Oxford Science Enterprises, Jameel Investment Management Company, UK Research and Innovation, Cedars-Sinai Intellectual Property Company.
Vivid Dx is headquartered in Oxford, United Kingdom.
Vivid Dx is a diagnostics company that focuses on pathogen detection and antimicrobial resistance testing services.
Vivid Dx is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vivid Dx — Funding & Investors." VCBacked, July 28, 2026, https://www.vcbacked.co/company/vivid-dx. Accessed August 1, 2026.
VCBacked. (2026). Vivid Dx — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/vivid-dx
{{cite web |title=Vivid Dx — Funding & Investors |url=https://www.vcbacked.co/company/vivid-dx |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated